Summit Therapeutics Inc. Q2 2025 10-Q Filing

Ticker: SMMT · Form: 10-Q · Filed: Aug 11, 2025 · CIK: 1599298

Summit Therapeutics Inc. 10-Q Filing Summary
FieldDetail
CompanySummit Therapeutics Inc. (SMMT)
Form Type10-Q
Filed DateAug 11, 2025
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, SEC Filing, Quarterly Report

Related Tickers: SMMT

TL;DR

**SMMT filed its Q2 2025 10-Q. All looks standard so far.**

AI Summary

Summit Therapeutics Inc. filed its quarterly report for the period ended June 30, 2025. The company is incorporated in Delaware and its principal executive offices are located in Miami, Florida. Its common stock trades on The Nasdaq Stock Market LLC under the ticker symbol SMMT.

Why It Matters

This filing provides an update on Summit Therapeutics' financial and operational status for the second quarter of 2025, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This is a standard quarterly report filing with no immediate red flags or significant new information presented in the provided excerpt.

Key Players & Entities

  • Summit Therapeutics Inc. (company) — Registrant
  • June 30, 2025 (date) — Quarterly period end date
  • Delaware (jurisdiction) — State of incorporation
  • Miami, FL (location) — Address of principal executive offices
  • SMMT (ticker) — Trading symbol for common stock
  • The Nasdaq Stock Market LLC (company) — Exchange where common stock is registered

FAQ

What is the Commission File Number for Summit Therapeutics Inc.?

The Commission File Number for Summit Therapeutics Inc. is 001-36866.

What is the par value of Summit Therapeutics Inc.'s common stock?

The par value of Summit Therapeutics Inc.'s common stock is $0.01 per share.

In which state was Summit Therapeutics Inc. incorporated?

Summit Therapeutics Inc. was incorporated in Delaware.

What is the telephone number for Summit Therapeutics Inc.'s principal executive offices?

The telephone number for Summit Therapeutics Inc.'s principal executive offices is 305 - 203-2034.

On which exchange is Summit Therapeutics Inc.'s common stock registered?

Summit Therapeutics Inc.'s common stock is registered on The Nasdaq Stock Market LLC.

Filing Stats: 4,434 words · 18 min read · ~15 pages · Grade level 18.8 · Accepted 2025-08-11 16:23:09

Key Financial Figures

  • $0.01 — nge on which registered Common Stock, $0.01 par value per share SMMT The Nasdaq S

Filing Documents

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 4 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 7 Notes to Unaudited Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 21

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 32

Controls and Procedures

Item 4. Controls and Procedures 32 PART II

Legal Proceedings

Item 1. Legal Proceedings 34

Risk Factors

Item 1A. Risk Factors 34

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 35

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 35

Other Information

Item 5 Other Information 35

Exhibits

Item 6. Exhibits 36

Signatures

Signatures 37 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), regarding the future financial performance, business prospects and growth of Summit Therapeutics Inc., that involve substantial risks and uncertainties. All statements contained in this Quarterly Report on Form 10-Q, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: the ability to develop a successful product candidate under the License Agreement (as defined below); our ability to raise sufficient additional funds to make payments under the License Agreement, and fund ongoing operations and capital needs; the timing of and the ability to effectively execute clinical development of ivonescimab; the timing, costs, conduct and outcomes of clinical trials for any product candidates, including ivonescimab; our plans with respect to possible future collaborations and partnering arrangements; the potential benefits of possible future acquisitions or investments in other businesses, products or technologies; our plans to pursue research and development of other future product

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Summit Therapeutics Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (Unaudited) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 297,872 $ 104,862 Restricted cash 319 325 Short-term investments — 307,487 Prepaid expenses and other current assets 11,049 11,076 Total current assets 309,240 423,750 Non-current assets: Property and equipment, net 690 254 Operating lease right-of-use assets 5,552 7,144 Goodwill 2,039 1,864 Other assets 6,516 2,548 Total assets $ 324,037 $ 435,560 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 22,982 $ 4,636 Accrued liabilities 26,148 19,554 Accrued compensation 6,592 11,977 Operating lease liabilities, current portion 3,118 3,765 Other current liabilities 1,485 1,797 Total current liabilities 60,325 41,729 Non-current liabilities: Operating lease liabilities, net of current portion 2,435 3,453 Other non-current liabilities 1,838 1,630 Total liabilities 64,598 46,812 Commitments and contingencies (Note 13) Stockholders' equity: Preferred stock, $ 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at June 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.01 par value: 1,000,000,000 shares authorized; 742,806,672 and 737,626,004 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 7,428 7,376 Additional paid-in capital 2,097,957 1,598,230 Accumulated other comprehensive loss ( 2,752 ) ( 2,285 ) Accumulated deficit ( 1,843,194 ) ( 1,214,573 ) Total stockholders' equity 259,439 388,748 Total liabilities and stockholders' equity $ 324,037 $ 435,560 The accompanying notes are an integral part of the unaudited condensed consolidated financial statements. 4 Summit Therapeutics Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and p

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.